That is also the principle behind active pharmacovigilance. For example, we can use sentinel physician networks for new products coming on the market. We can also consult specialists who are likely to be caring for this type of patient, and solicit active reporting, rather than relying on a passive system.
On March 11th, 2008. See this statement in context.